CSDC2

Across TCGA pan-cancer cohorts, CSDC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CSDC2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CSDC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CSDC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where CSDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.915	0.651	.002	27	view →
LUAD	OS	Median	III,IV	0.797	0.445	.004	16	view →
GBM	DFS	Tertile	All	0.494	0.260	.016	10	view →
PDAC	OS	Median	All	0.415	0.868	.047	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CSDC2–CCRCC (OS)

Open the CCRCC breakdown →